Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. (NASDAQ: INVA) is a diversified healthcare holding company whose news flow reflects its dual focus on royalty-based income and commercial-stage infectious disease and critical care therapies. Company announcements frequently highlight performance of its royalties portfolio tied to GSK respiratory products RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, alongside updates from Innoviva Specialty Therapeutics (IST), its critical care and infectious disease platform.
News releases from Innoviva and IST cover quarterly financial results, including royalty revenue and net product sales, as well as regulatory milestones and product launches. Examples include FDA acceptance and Priority Review of the New Drug Application for zoliflodacin, subsequent FDA approval of NUZOLVENCE® (zoliflodacin) for uncomplicated urogenital gonorrhea, and the U.S. launch of ZEVTERA® (ceftobiprole) for serious bacterial infections such as Staphylococcus aureus bloodstream infections, ABSSSI, and CABP.
Investors and healthcare professionals can also find coverage of clinical and scientific data presentations at major conferences like IDWeek, where Innoviva Specialty Therapeutics presents Phase 3 results, subgroup analyses, pharmacokinetic-pharmacodynamic studies, and microbiologic surveillance for agents including zoliflodacin, ZEVTERA, XACDURO®, and XERAVA®. Additional news items describe capital allocation decisions, such as share repurchase authorizations, strategic investments in healthcare companies, and licensing or acquisition of new platforms and assets.
This INVA news page aggregates these updates in one place, making it easier to track earnings announcements, regulatory decisions, conference presentations, and portfolio developments. Readers interested in Innoviva’s evolving role in respiratory royalties, antibiotic development, and critical care therapeutics can use this feed to monitor key events and company disclosures over time.
Innoviva, Inc. (NASDAQ: INVA) announced its second-quarter financial results for 2021, reporting gross royalty revenues of $104.3 million, a 44% year-over-year increase. Key contributors included RELVAR®/BREO® ELLIPTA® with $65.9 million and TRELEGY® ELLIPTA®, which saw a 69% increase in global net sales. Income before taxes rose 15% to $136.2 million. The company successfully repurchased 32% of its equity from GSK for $394.1 million. Cash and receivables totaled $140.4 million as of June 30, 2021. CEO Pavel Raifeld highlighted the company's strategic investments and operational excellence.
Innoviva, Inc. (NASDAQ: INVA) announced a definitive agreement to purchase GSK's 32% equity stake, constituting approximately 32 million shares, for $12.25 each, totaling $392 million. This transaction represents a 3% discount to the recent average stock price. CEO Pavel Raifeld emphasized that the buyback enhances shareholder alignment and supports the company's strategic goals. Innoviva remains confident in its collaboration with GSK for respiratory products, anticipating continued significant value creation for shareholders.
Innoviva, Inc. (NASDAQ:INVA) reported Q1 2021 financial results showing gross royalty revenues of $89.0 million, a year-over-year increase of 8%. Key contributors included RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA®. Income before income taxes rose 36% to $129.4 million. Total cash and equivalents reached $279.6 million. The company invested $20.0 million in Armata, acquiring 60% ownership. CEO Pavel Raifeld acknowledged competitive challenges but expressed optimism for future growth.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has successfully closed the second and final tranche of a $20 million private placement with Innoviva, Inc. (NASDAQ: INVA). This transaction raised approximately $13.9 million through the issuance of 4,285,935 common shares and warrants at $3.25 each, following a notable 99% shareholder approval. The first tranche, completed on January 26, 2021, raised $6.1 million. Following both closings, Armata now has 24,940,442 shares outstanding and warrants for 16,649,465 additional shares.
Innoviva, Inc. (NASDAQ: INVA) reported fourth-quarter 2020 gross royalty revenues of $93.9 million, primarily from GSK's RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA® products. Income before taxes rose 29% to $90.8 million. Significant net sales growth was noted: 5% for RELVAR®, 10% for ANORO®, and 42% for TRELEGY®. The company effectively managed its capital, investing nearly $400 million in promising assets and forming strategic partnerships to enhance returns. Cash and equivalents totaled $243.3 million as of year-end.
Armata Pharmaceuticals (NYSE American: ARMP) announced a securities purchase agreement with Innoviva (Nasdaq: INVA), securing approximately $20 million in gross proceeds. The funds will support Armata's bacteriophage development programs, including the FDA-cleared SWARM-P.a. study for AP-PA02 targeting Pseudomonas aeruginosa infections. The agreement includes the purchase of 6.2 million shares at $3.25 each and warrants, scheduled in two tranches. Armata aims to achieve significant clinical milestones in 2021 and 2022, advancing its pipeline for combatting antibiotic-resistant infections.
Innoviva, Inc. (NASDAQ: INVA) reported third-quarter 2020 financial results, showcasing gross royalty revenues of $92.2 million, primarily from GSK's sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA®. Notably, RELVAR®/BREO® ELLIPTA® sales surged by 38% year-over-year. However, income before taxes decreased by 12% to $50.5 million. The company's total cash and equivalents stood at $474.9 million. Innoviva's investment in Entasis Therapeutics now totals 52.6%. The FDA approved TRELEGY® for asthma, enhancing growth prospects.